JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.
Teleflex’s Growth Drivers In Question: Analyst Predicts Potential Business Realignment
Needham analyst Mike Matson
JP Morgan Downgrades Cyteir Therapeutics to Neutral
JP Morgan analyst Anupam Rama downgrades Cyteir Therapeutics (NASDAQ:CYT) from Overweight to Neutral.
Related Posts
HF Foods Group Receives Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard
HF Foods Group Inc. (the “Company”) received a Staff Delisting Determination (the “Staff Determination”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC
Warren Buffett-Backed BYD Has Already Surged Past Tesla In Sales — Now It Has A $14B Game Plan For Making EVs More Intelligent
BYD's goal is to boost the proportion of vehicles equipped with smart driving systems, currently at 57%, and plans to unveil more than 10 LiDAR-equipped models in 2024.
Wells Fargo Maintains Equal-Weight on Magna International, Raises Price Target to $63
Wells Fargo analyst Colin Langan maintains Magna International (NYSE:MGA) with a Equal-Weight and raises the price target from $60 to $63.